| Acne |
No |
| Active substance |
Rivaroxaban |
| Also known as |
BAY 59-7939 |
| Aromatization |
No |
| Blood pressure |
No significant effect on blood pressure |
| Chemical name |
Rivaroxaban |
| Dosage (medical) |
10 mg, 15 mg, or 20 mg tablets once daily, depending on the condition being treated |
| Dosage (sports) |
N/A |
| Effects |
Reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, treats deep vein thrombosis and pulmonary embolism, prevents blood clots in certain patients |
| Formula |
C19H18ClN3O5S |
| Half-life |
5 to 9 hours in healthy individuals, up to 11 to 13 hours in the elderly |
| HBR |
No |
| Hepatotoxicity |
No |
| Lab Test |
Anti-factor Xa activity can indirectly measure its effect but is not routinely monitored |
| Main action |
Inhibits thrombin formation by directly targeting Factor Xa |
| Side effects |
Bleeding, anemia, liver enzyme changes, dizziness, headache, rash |
| Storage conditions |
Store at 15В°C to 30В°C (59В°F to 86В°F) in a dry place |
| Substance class |
Anticoagulant |
| Trade name |
Xarelto |
| Use in sports |
Not typically used in sports |
| WAREHOUSE |
International Warehouse 2 |
| Water Retention |
No |
| Manufacturer |
Bayer |
